The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...

It was also confirmed that HDCA inhibited the Epiregulin (EREG)/Epidermal Growth Factor Receptor (EGFR) pathway by activating FXR, and a negative correlation between FXR and EREG was analyzed in CRC ...

Analyst Judah Frommer from Morgan Stanley maintained a Hold rating on ProKidney (PROK – Research Report) and keeping the price target at ...

Additionally, this may allow MS profiling to clarify key points in EGFR pathways for further targeting, to provide a firmer scientific basis for MS profiling technology, and enable development of ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor ...

show that EGFR inhibitors can have a dramatic impact in early-stage lung cancer and should be used as early as possible in the treatment pathway. That's important for AZ, as Tagrisso is starting ...

How can we tell whether EGFR inhibitors effectively inhibit the key pathways driving EGFR-mediated radioresistance? Considering tumor instability and heterogeneity, how can we optimize the ...

Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...

Dr Zaheer Mangera shares insights into the lung cancer pathway and the benefits and challenges of early diagnosis and lung ...